Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-22 02:33:46 Source:businessViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:Jodie Turner
Next:Auburn running back Brian Battie on ventilator after weekend shooting in Florida, coach says
You may also like
- Forensic psychiatrist reveals the different types of stalkers
- BBC Countryfile star Adam Henson's wife wrote heartbreaking goodbye letters after cancer diagnosis
- LeBron James UNFOLLOWS Diddy on Instagram after video of assault on ex
- Demi Moore, 61, says full
- National Television Awards 2024 nominations: Michelle Keegan and Leo Woodall go head
- Nina Dobrev hospitalized with a neck brace due to serious e
- Queen Camilla reveals she's seen the first season of Bridgerton
- UN Security Council rejects Russia
- Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership